IDO1 and TDO Modulator Compounds for Kynurenine Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a strong unmet need for new compounds that inhibit indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO) enzymes to address various disease indications related to immunosuppression, tumor growth, infectious diseases, inflammatory and autoimmune diseases, neurodegenerative disorders, and cardiovascular diseases, as existing inhibitors are limited in efficacy and availability.
Innovation Solution
Development of compounds, such as those represented by Formula I(a), which selectively modulate IDO1, TDO, or both, to regulate tryptophan metabolism and balance kynurenine pathway metabolites, thereby addressing the dysregulation that leads to these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing IDO and TDO inhibitors are used, then some immunosuppression effects are achieved, but their efficacy is limited and availability is restricted
Solution Approach 1:
The patent segments the inhibition approach by developing separate compound series for IDO1 inhibition and TDO inhibition, allowing optimization of each enzyme's inhibition independently. This enables broader availability through multiple compound options rather than relying on a single inhibitor with limited efficacy
Solution Approach 2:
The patent employs systematic variation of chemical parameters (substituents R1-R6, molecular weight, logP values) to generate multiple compounds with different potency profiles and pharmacokinetic properties. This parameter optimization across compound series 1 and 2 expands the available effective inhibitors beyond what existing single agents provide
2Reliability
If IDO1 and TDO activity is strongly inhibited, then immunosuppression is reversed and immune responses are enhanced, but tryptophan depletion and kynurenine metabolite accumulation worsen
Solution Approach 1:
The patent optimizes compound parameters to achieve selective inhibition with appropriate potency (IC50 values in specific ranges) that balances immune enhancement with metabolic homeostasis. By controlling inhibition strength through molecular design, the compounds reverse immunosuppression while minimizing harmful metabolic disruptions
Solution Approach 2:
The patent designs compounds that modulate enzyme activity to restore balance in the kynurenine pathway. The selective inhibition creates a feedback effect where tryptophan metabolism is regulated to prevent excessive depletion while reducing immunosuppressive kynurenine metabolite accumulation, thereby enhancing immune responses
3Adaptability or versatility
If selective IDO1 or TDO inhibition is achieved, then specific disease indications are treated, but the complexity of compound design increases
Solution Approach 1:
The patent divides the complex design challenge into two separate but parallel programs: one for IDO1 selective inhibitors and another for TDO selective inhibitors. Each program has its own structural framework (series 1 with specific core structure, series 2 with alternative core) and substitution patterns, making the design complexity manageable while achieving broad disease coverage through dual-path development
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively modulate IDO1 and TDO activity, potentially reversing immunosuppression, inhibiting tumor growth, enhancing immune responses, and treating a wide range of diseases including HIV, tumors, autoimmune disorders, neurodegenerative diseases, and cardiovascular conditions.
Implementation Method 1
The essential amino acid tryptophan is degraded through the kynurenine pathway, of which the first and rate limiting step is catalyzed by heme-containing oxidoreductase enzymes, including indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO), that convert tryptophan to N-formylkynurenine.
Implementation Method 2
The present disclosure relates to compounds which inhibit indoleamine-2,3-dioxygenase (IDO), specifically indoleamine 2,3-dioxygenase 1 (IDO1), and tryptophan-2,3-dioxygenase (TDO).
Data Source
AI summary
Disclosed are compounds of Formula I (a) or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, R5, R6, R7, G1, G2 and Ring A are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.